Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology Jg. 17; H. 3; S. 367 - 377
Hauptverfasser:	Chan, Arlene, Delaloge, Suzette, Holmes, Frankie A, Moy, Beverly, Iwata, Hiroji, Harvey, Vernon J, Robert, Nicholas J, Silovski, Tajana, Gokmen, Erhan, von Minckwitz, Gunter, Ejlertsen, Bent, Chia, Stephen K L, Mansi, Janine, Barrios, Carlos H, Gnant, Michael, Buyse, Marc, Gore, Ira, Smith, John, Harker, Graydon, Masuda, Norikazu, Petrakova, Katarina, Zotano, Angel Guerrero, Iannotti, Nicholas, Rodriguez, Gladys, Tassone, Pierfrancesco, Wong, Alvin, Bryce, Richard, Ye, Yining, Yao, Bin, Martin, Miguel
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 01.03.2016 Elsevier Limited
Schlagworte:	Abdomen Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - surgery Cancer therapies Chemotherapy Chemotherapy, Adjuvant Corporate sponsorship Data collection Disease-Free Survival Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Hematology, Oncology, and Palliative Medicine Humans Internationality Kaplan-Meier Estimate Mastectomy - methods Medical prognosis Middle Aged Neoplasm Invasiveness - pathology Neoplasm Staging Pain Population Proportional Hazards Models Quinolines - administration & dosage Quinolines - adverse effects Receptor, ErbB-2 - metabolism Survival Analysis Trastuzumab - administration & dosage Trastuzumab - adverse effects Treatment Outcome Tumors Womens health
ISSN:	1470-2045, 1474-5488, 1474-5488
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!